24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Long-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?Failing Kidneys Could Bring Higher Dementia RiskDementia Risk Rises as Years Lived With Type 2 Diabetes IncreasesHead Injury, Alzheimer's Appear to Affect Brain in Similar WaysBrain Injuries Raise Long-Term Risk of StrokeResearch Shows Links Between Gum Disease and Alzheimer'sAssisted Living Centers Can Do More for Dementia Patients, Experts SayDiminished Hearing, Vision Together Could Be Risk Factor for Dementia6 Steps to Reduce Caregiver StressLoneliness in Mid-Life Linked to Higher Odds for Alzheimer'sDrug Used in Cancer Patients Might Help Treat Alzheimer's'Non-Drug' Approaches Can Fight Depression in People With DementiaSuicide Attempts Spike Soon After Dementia DiagnosisCould a New Drug Help Ease Alzheimer's?AHA News: Dementia May Be a Risk Factor for Infection But Not Death From COVID-19Your Eyes May Signal Your Risk for Stroke, DementiaEven 1 Concussion May Raise Your Odds for Dementia LaterAlzheimer's Patients Are Being Given Too Many MedsMany Blacks, Hispanics Believe They'll Get Worse Care If Dementia StrikesAlzheimer's May Strike Women and Men in Different WaysHistory of Mental Illness Tied to Earlier Onset of Alzheimer's DiseaseAHA News: Black, Hispanic Families Hit Hardest by DementiaWhy Some 'Super Ager' Folks Keep Their Minds Dementia-FreeDementia Seen in Younger Adults Shows Even More Brain Damage Than Alzheimer's
Questions and AnswersLinks
Related Topics

Lilly to Seek FDA Approval for New Alzheimer's Drug

HealthDay News
by Robin Foster and Robert Preidt
Updated: Jun 25th 2021

new article illustration

FRIDAY, June 25, 2021 (Healthday News) -- Fresh on the heels of the U.S. Food and Drug Administration's approval of the controversial Alzheimer's drug Aduhelm, the maker of a second medicine that works in similar fashion said Thursday it hopes to apply for approval of its medication later this year.

Eli Lilly said findings from a mid-stage clinical trial of 272 patients with early Alzheimer's suggest the drug donanemab slows declines in thinking and daily function, the Associated Press reported.

The company said it plans to examine the drug in a larger, late-stage trial that will complete enrollment by the end of the year, followed by an 18-month treatment period.

Donanemab has already received a "breakthrough therapy" designation from the FDA, which is meant to hasten development and review of drugs considered to be potentially better than existing treatments. Donanemab, like Aduhelm, clears an Alzheimer's-linked protein called beta-amyloid from the brain.

Lilly may be able to file its application for approval in the next two or three months since the drugmaker appears to have all the data it needs, Dr. Vamil Divan, an analyst who covers the company for Mizhuho Securities USA, told the AP.

Just a few weeks ago, the FDA approved Aduhelm from Biogen, over the objections of independent advisers who said the drug hasn't been shown to help slow Alzheimer's. The FDA said it was "reasonably likely" that Aduhelm would help patients, the AP reported.

Aduhelm -- the first new Alzheimer's drug approved in the United States in nearly 20 years -- is the only treatment likely capable of changing the course of the disease, rather than slowing symptoms like thinking/memory problems and anxiety, U.S. regulators said at the time.

On Wednesday, Biogen said another experimental Alzheimer's drug it developed with Eisai Co. was given breakthrough designation by the FDA, and that the drug, lecanemab, is being assessed in a late-stage study, the AP reported.

Some 6 million Americans and many more worldwide have Alzheimer's disease, which slowly damages areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Lilly and several other drugmakers have previously failed in attempts to find a treatment that slows the progression of the mind-robbing disease.

More than four years ago, Lilly said another potential drug it developed called solanezumab did not work better than a placebo in a study of over 2,100 people. That drug also aimed to clear potentially harmful protein from the brain.

More information

Visit the Alzheimer's Association for more on Alzheimer's disease.



SOURCES: Eli Lilly Co, news release, June 24, 2021; Associated Press